Welcome to our dedicated page for Maravai Lifesciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai Lifesciences Holdings stock.
Maravai LifeSciences Holdings, Inc. reports recurring developments as a life sciences supplier of reagents and services for drug therapy, diagnostics, vaccine and human disease research. Company updates center on its TriLink nucleic acid synthesis business, including mRNA, oligonucleotides and CleanCap-related technologies, and its Cygnus biologics safety testing business, including host cell protein ELISA kits, impurity detection assays, reagents and services.
News about MRVI commonly covers quarterly financial results, segment revenue trends, guidance, restructuring and operating cost initiatives, investor conference participation, executive and board changes, and product or commercial updates tied to researchers, biotech innovators, vaccine developers, diagnostics companies and cell and gene therapy customers.
Maravai LifeSciences Holdings (MRVI) has priced its upsized initial public offering at $27.00 per share, offering 60,000,000 shares of Class A common stock, resulting in gross proceeds of $1.62 billion. The shares will commence trading on the Nasdaq under the ticker MRVI on November 20, 2020, with the offering closing expected by November 24, 2020. The underwriters have a 30-day option to buy an additional 9,000,000 shares. Maravai specializes in life science reagents and services crucial for drug development and diagnostics.